---
title: "China Traditional Chinese Medicine says NMPA approves launch of Xingpi Jieyu tablets for depression"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298040727.md"
description: "China Traditional Chinese Medicine Holdings announced that China's NMPA has approved the market launch of Xingpi Jieyu Tablets, a Class 1.1 TCM innovative drug for mild-to-moderate depression. The marketing authorization holder is Sinopharm Group Tongjitang (Guizhou) Pharmaceutical. Phase III trials completed in 2024 demonstrated the drug's safety and efficacy, showing outperformance versus placebo. This approval expands the group's proprietary Chinese medicine portfolio."
datetime: "2026-09-04T12:46:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298040727.md)
  - [en](https://longbridge.com/en/news/298040727.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298040727.md)
generator: "portal-rs"
---

# China Traditional Chinese Medicine says NMPA approves launch of Xingpi Jieyu tablets for depression

-   China Traditional Chinese Medicine Holdings said China’s NMPA cleared its Class 1.1 TCM innovative drug Xingpi Jieyu Tablets for market launch. \* Marketing authorization holder: Sinopharm Group Tongjitang (Guizhou) Pharmaceutical, a group subsidiary. \* Drug targets mild-to-moderate depression; Phase III trial completed in 2024 showed safety, efficacy, outperformance versus placebo. \* Approval expands the group’s proprietary Chinese medicine portfolio; earnings impact depends on production, sales, reimbursement, tenders, competition. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260904-12321999), on September 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [00570.HK](https://longbridge.com/en/quote/00570.HK.md)
- [01099.HK](https://longbridge.com/en/quote/01099.HK.md)
- [600511.CN](https://longbridge.com/en/quote/600511.CN.md)

## Related News & Research

- [Sinopharm Group Signs Three-Year Supply Purchase Agreement With CNPGC](https://longbridge.com/en/news/304858315.md)
- [China TCM Group Launches Connected Facility Upgrades in Mainland China](https://longbridge.com/en/news/299052240.md)
- [China TCM expects H1 loss of RMB 800 million-RMB 850 million](https://longbridge.com/en/news/293043444.md)
- [M Stanley: SINOPHARM  3Q26 Results Reflect Continued Pressure on Domestic Industry](https://longbridge.com/en/news/303044955.md)
- [TRAD CHI MED Warns Interim Loss to Widen to Up to RMB850M](https://longbridge.com/en/news/293151600.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**